Aripiprazole Tablet
Product Images NDC 71335-1515

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 71335-1515). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure4 (Aripiprazole Fig4)

A chart titled 'Aripiprazole Fold Change and 90% CI' showing pharmacokinetic changes (AUC and Cmax) relative to reference across special populations including CYP2D6 metabolizer status, gender, age, hepatic impairment, and renal impairment. Data points are presented with error bars indicating confidence intervals for each group comparison.*

FDA Label Image

Figure5 (Aripiprazole Fig5)

A chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing the effects of various factors on pharmacokinetics (PK) of dehydro-aripiprazole. It compares AUC and Cmax fold changes relative to reference for CYP2D6 metabolizer status, gender, age, hepatic impairment, and renal impairment, with error bars indicating 90% confidence intervals.*

FDA Label Image

Structure (Aripiprazole Struct)

Chemical structure of Aripiprazole showing its molecular components including chlorine-substituted aromatic rings, piperazine ring, and quinolinone group.*

FDA Label Image

Aripiprazole_fig_01 (Aripiprazole Fig 01)

A chart showing the effect of various drugs on the pharmacokinetics (AUC and Cmax) of aripiprazole, illustrating fold changes and 90% confidence intervals for inhibitors, inducers, gastric acid blockers, and other drugs compared to a reference without interacting drugs.*

FDA Label Image

Aripiprazole_fig_02 (Aripiprazole Fig 02)

A chart showing the effect of various drugs on the pharmacokinetics (AUC and Cmax) of Aripiprazole. It lists CYP3A4 inhibitor (ketoconazole), CYP2D6 inhibitor (quinidine), CYP3A4 inducer (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam), comparing their change on Aripiprazole exposure relative to a reference without interacting drug. Data is presented as fold change with 90% confidence intervals.*

FDA Label Image

Aripiprazole_fig_03 (Aripiprazole Fig 03)

A forest plot chart showing the effect of Aripiprazole on the pharmacokinetics (PK) of various drugs. The chart compares fold changes and 90% confidence intervals of parameters like AUC, Cmax, and INR for drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram, relative to a reference without interacting drug.*

FDA Label Image

Figure6 (Aripiprazole Fig 06)

A Kaplan-Meier survival curve chart comparing the proportion with relapse over time between Aripiprazole and placebo groups. The X-axis indicates the number of days in the study, and the Y-axis shows the proportion with relapse. A table below the graph shows the number of subjects at risk at different time points for each group.*

FDA Label Image

Aripiprazole_fig_07 (Aripiprazole Fig 07)

A Kaplan-Meier plot showing the proportion of subjects with relapse over days from randomization for Aripiprazole versus placebo. The x-axis represents days from randomization (0 to 182), and the y-axis shows the proportion with relapse (0 to 1.0). Aripiprazole group data is plotted with a solid blue line, placebo with a dashed red line. A table below the graph lists the number of subjects at risk over time for each group.*

FDA Label Image

Aripiprazole_fig_08 (Aripiprazole Fig 08)

A line graph showing the proportion with relapse over time for Aripiprazole and placebo groups. The x-axis represents days from randomization up to 364 days, and the y-axis shows the proportion with relapse, ranging from 0.0 to 1.0. The graph includes data points and a table of number of subjects at risk at various time intervals for both groups.*

FDA Label Image

Label (Lbl713351515)

Label for Aripiprazole 10 mg tablet, packaged by Bryant Ranch Prepack. The label compares the product to Abilify 10 mg tablet by Ajanta Pharma Limited. It includes a storage temperature recommendation of 20°-25°C (68°-77°F), a safety warning to keep drugs out of reach of children, and displays the NDC number 71335-1515-1. The label also shows a lot number and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.